MYH9 Inhibitors
MYH9 inhibitors belong to a specific chemical class of compounds that target the MYH9 protein. MYH9, also known as myosin-9, is a motor protein that plays a crucial role in cellular processes involving the cytoskeleton, such as cell migration, adhesion, and contractility. The inhibitors designed for this class specifically target and modulate the activity of MYH9, aiming to interfere with its normal function. These inhibitors are typically small-molecule compounds or biologics that exhibit a high degree of selectivity towards MYH9, avoiding interactions with other cellular components.
By doing so, they effectively disrupt the normal functioning of MYH9 within the cells without affecting other critical cellular processes. The modulation of MYH9 activity by these inhibitors could offer valuable insights into its biological functions and pave the way for potential applications in various. Researchers studying MYH9 inhibitors aim to unravel the underlying mechanisms of cell motility and cellular processes where MYH9 is involved, which could potentially contribute to advancing our understanding of cell biology and various physiological processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Blebbistatin is a small-molecule inhibitor that selectively targets non-muscle myosin-2 (NM2) isoforms, including MYHIt interferes with the ATPase activity of the myosin motor, preventing actin-myosin interactions and thus inhibiting cellular contractility. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $112.00 $449.00 $673.00 $1224.00 | 2 | |
ML-9 is a potent inhibitor of myosin light chain kinase (MLCK), an upstream regulator of MYHBy blocking MLCK activity, ML-9 indirectly inhibits MYH9 function. | ||||||
CCG 203971 | 1443437-74-8 | sc-507360 | 10 mg | $89.00 | ||
CCG-203971 is a specific small-molecule inhibitor of MYH9 ATPase activity. It prevents the hydrolysis of ATP by the MYH9 motor domain, interfering with its contractile function. | ||||||
Rhosin | 1173671-63-0 | sc-507401 | 25 mg | $555.00 | ||
This cell-permeable peptide specifically interferes with the activation of RhoA, a key regulator of the Rho signaling pathway that influences MYH9-mediated cellular contractility. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
R-Roscovitine is a cyclin-dependent kinase (CDK) inhibitor with potential anti-cancer properties. It can also affect MYH9 function indirectly through its impact on CDKs involved in regulating cellular motility. | ||||||
Thiazovivin | 1226056-71-8 | sc-361380 sc-361380A | 10 mg 25 mg | $284.00 $634.00 | 15 | |
Thiazovivin is a ROCK inhibitor that indirectly affects MYH9 function by targeting ROCK-mediated actomyosin contractility. | ||||||
GSK 429286 | 864082-47-3 | sc-361200 sc-361200B sc-361200A | 1 mg 5 mg 10 mg | $40.00 $125.00 $235.00 | ||
This small-molecule inhibitor targets Rho-associated coiled-coil containing protein kinase (ROCK) and can indirectly influence MYH9 function through its impact on actomyosin contractility. | ||||||